Planned and Unplanned Mid-Study Updates Pose Major Challenge to Clinical Trial Timelines, According to Tufts Center for the Study of Drug Development
02 mars 2021 09h00 HE
|
Tufts Center for the Study of Drug Development
Tufts Center for the Study of Drug Development Analysis Finds Larger Pharmaceutical Companies Experience Longer Delays due to Mid-Study Updates BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Planned...
Rénibus Therapeutics to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference
25 févr. 2021 09h00 HE
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Rénibus Therapeutics, Inc., a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease,...
vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
17 févr. 2021 16h05 HE
|
vTv Therapeutics Inc.
Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021 Strategic Partner in Asia and Pacific Rim, Newsoara...
Avricore Health Completes $1.54 Million Financing and Grants Options
12 févr. 2021 08h30 HE
|
Avricore Health Inc.
VANCOUVER, British Columbia, Feb. 12, 2021 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) announces it has closed its non-brokered private placement announced on...
Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results
10 févr. 2021 16h05 HE
|
Fluidigm Corporation
Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to...
Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
04 févr. 2021 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Avricore Health Announces $1.54 Million Financing
03 févr. 2021 20h05 HE
|
Avricore Health Inc.
VANCOUVER, British Columbia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) announces a non-brokered private placement of up to 7,000,000 units...
AXIM® Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients
03 févr. 2021 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological...
NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
02 févr. 2021 14h05 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis
29 janv. 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...